How to buy Immutep shares | A$0.25

Immutep Limited is a biotechnology business based in Australia. Immutep shares (IMM) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $0.25 – an increase of 2.04% over the previous week. Immutep has a trailing 12-month revenue of around $13.7 million.

How to buy shares in Immutep

1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
3. Search for Immutep . Find the share by name or ticker symbol: IMM. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Immutep reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At today's price of $0.25, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
6. Check in on your investment. Congratulations, you own a part of Immutep . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

How has coronavirus impacted Immutep 's share price?

Since the stock market crash in March caused by coronavirus, Immutep 's share price has had significant negative movement.

Its last market close was $0.25, which is 39.76% down on its pre-crash value of $0.415 and 150.00% up on the lowest point reached during the March crash when the shares fell as low as $0.1.

If you had bought $1,000 worth of Immutep shares at the start of February 2020, those shares would have been worth $876.92 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $769.23.

Immutep share price

Use our graph to track the performance of IMM stocks over time.

Immutep shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	AUDA$0.25
52-week range	AUDA$0.1 - AUDA$0.445
50-day moving average	AUDA$0.2302
200-day moving average	AUDA$0.1829
Target price	AUDA$0.08
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	AUDA$-0.006

Share Trading Account Offer

IG Share Trading Offer

AUD 8

Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian and international shares

• Brokerage - AU shares: From AUD 5 or 0.05%
• Brokerage - US shares: USD 0
• Sign-up process: Instant
• Support - After hours: Yes

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Immutep stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Immutep Limited by TradingView

Immutep price performance over time

Historical closes compared with the close of A$0.25 on 2020-10-22

1 week (2020-10-15)	2.04%
1 month (2020-09-23)	-1.96%
3 months (2020-07-22)	25.00%
6 months (2020-04-22)	56.25%

1 year (2019-10-22)	-7.41%
2 years (2018-10-22)	-45.28%
3 years (2017-10-20)	-13.19%
5 years (2015-10-22)	-56.60%

Immutep financials

Revenue TTM	$13.7 million
Gross profit TTM	$-6,656,699
Return on assets TTM	-21.62%
Return on equity TTM	-46.69%
Profit margin	-98.03%
Book value	0.068
Market capitalisation	$120.8 million

TTM: trailing 12 months

Immutep share dividends

We're not expecting Immutep to pay a dividend over the next 12 months.

Have Immutep 's shares ever split?

Immutep 's shares were split on a 1:10 basis on 4 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immutep shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Immutep shares which in turn could have impacted Immutep 's share price.

Immutep share price volatility

Over the last 12 months, Immutep 's shares have ranged in value from as little as $0.1 up to $0.445. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Immutep 's is 1.343. This would suggest that Immutep 's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Immutep overview

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Frequently asked questions

• What percentage of Immutep is owned by insiders or institutions?

  Currently 6.409% of Immutep shares are held by insiders and 6.848% by institutions.

• When does the fiscal year end for Immutep ?

  Immutep 's fiscal year ends in June.

• Where is Immutep based?

  Immutep 's address is: 95 Pitt Street, Sydney, NSW, Australia, 2000

• What is Immutep 's ISIN number?

  Immutep 's international securities identification number is: AU000000IMM6